EGFR and non-small cell lung carcinoma: In the present study, we retrospectively analyzed 123 NSCLC patients who were previously EGFR mutation positive and resistant to treatment with EGFR-TKIs, the median PFS in the immune four-drug combination group was better than that in the other two treatment regimen groups, which is consistent with the experimental result of the ORIENT-31 study.